Huons Global Co., Ltd. (084110.KQ)
KRW 46750.0
(-0.53%)
KRW 46750.0
(-0.53%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 151.92 Billion KRW | 25.67% |
| 2022 | 46.17 Billion KRW | 14.05% |
| 2021 | 103.09 Billion KRW | -8.03% |
| 2020 | 114.83 Billion KRW | 21.8% |
| 2019 | 93.56 Billion KRW | 11.6% |
| 2018 | 83.84 Billion KRW | 13.57% |
| 2017 | 73.82 Billion KRW | 107.86% |
| 2016 | 33.94 Billion KRW | 140.32% |
| 2015 | 16.86 Billion KRW | -63.66% |
| 2014 | 40.66 Billion KRW | 10.54% |
| 2013 | 36.79 Billion KRW | 55.92% |
| 2012 | 23.59 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 40.33 Billion KRW | 11.16% |
| 2024 Q1 | 35.81 Billion KRW | 18.16% |
| 2023 FY | - KRW | 25.67% |
| 2023 Q1 | 33.1 Billion KRW | -9.06% |
| 2023 Q4 | 29.54 Billion KRW | -27.36% |
| 2023 Q2 | 44.98 Billion KRW | 35.88% |
| 2023 Q3 | 40.67 Billion KRW | -9.58% |
| 2022 Q4 | 36.4 Billion KRW | 28.53% |
| 2022 Q1 | 28.47 Billion KRW | 19.85% |
| 2022 FY | - KRW | 14.05% |
| 2022 Q2 | 28.17 Billion KRW | -1.09% |
| 2022 Q3 | 28.32 Billion KRW | 0.54% |
| 2021 Q1 | 27.21 Billion KRW | -12.39% |
| 2021 Q2 | 26.26 Billion KRW | -3.47% |
| 2021 Q3 | 26.67 Billion KRW | 1.54% |
| 2021 Q4 | 23.76 Billion KRW | -10.91% |
| 2021 FY | - KRW | -8.03% |
| 2020 Q2 | 28.11 Billion KRW | 14.19% |
| 2020 Q3 | 31.03 Billion KRW | 10.38% |
| 2020 Q4 | 31.06 Billion KRW | 0.09% |
| 2020 Q1 | 24.62 Billion KRW | -3.0% |
| 2020 FY | - KRW | 21.8% |
| 2019 Q4 | 25.38 Billion KRW | -3.09% |
| 2019 Q3 | 26.19 Billion KRW | 33.67% |
| 2019 Q2 | 19.59 Billion KRW | -12.5% |
| 2019 Q1 | 22.39 Billion KRW | 39.25% |
| 2019 FY | - KRW | 11.6% |
| 2018 FY | - KRW | 13.57% |
| 2018 Q4 | 16.08 Billion KRW | -37.24% |
| 2018 Q3 | 25.62 Billion KRW | 20.65% |
| 2018 Q2 | 21.23 Billion KRW | 1.62% |
| 2018 Q1 | 20.89 Billion KRW | 14.78% |
| 2017 Q4 | 18.2 Billion KRW | -18.55% |
| 2017 Q1 | 14.23 Billion KRW | -4.56% |
| 2017 Q2 | 19.02 Billion KRW | 33.69% |
| 2017 Q3 | 22.35 Billion KRW | 17.47% |
| 2017 FY | - KRW | 107.86% |
| 2016 Q2 | 5.45 Billion KRW | 2.14% |
| 2016 Q4 | 14.91 Billion KRW | 34.07% |
| 2016 Q3 | 11.12 Billion KRW | 103.88% |
| 2016 Q1 | 5.34 Billion KRW | 21.36% |
| 2016 FY | - KRW | 140.32% |
| 2015 Q2 | 4.88 Billion KRW | 37.15% |
| 2015 Q4 | 4.4 Billion KRW | -31.64% |
| 2015 Q3 | 6.43 Billion KRW | 31.71% |
| 2015 FY | - KRW | -63.66% |
| 2015 Q1 | 3.56 Billion KRW | -59.43% |
| 2014 Q3 | 11.48 Billion KRW | 6.09% |
| 2014 Q1 | 9.56 Billion KRW | -1.06% |
| 2014 Q2 | 10.82 Billion KRW | 13.15% |
| 2014 Q4 | 8.78 Billion KRW | -23.49% |
| 2014 FY | - KRW | 10.54% |
| 2013 Q2 | 9.35 Billion KRW | 28.36% |
| 2013 FY | - KRW | 55.92% |
| 2013 Q1 | 7.28 Billion KRW | 29.53% |
| 2013 Q3 | 10.48 Billion KRW | 12.1% |
| 2013 Q4 | 9.67 Billion KRW | -7.75% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q4 | 5.62 Billion KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 581.09 Million KRW | -26045.471% |
| CMG Pharmaceutical Co., Ltd. | 5.59 Billion KRW | -2615.679% |
| Celltrion Pharm, Inc. | 54.22 Billion KRW | -180.187% |
| DongKook Pharmaceutical Co., Ltd. | 88.68 Billion KRW | -71.311% |
| Enzychem Lifesciences Corporation | -5.77 Billion KRW | 2731.393% |
| Humedix Co., Ltd. | 54.87 Billion KRW | -176.866% |
| Boditech Med Inc. | 36.48 Billion KRW | -316.374% |
| EuBiologics Co., Ltd. | -4.39 Billion KRW | 3559.359% |
| FutureChem Co.,Ltd | -591.25 Million KRW | 25795.93% |
| Huons Co., Ltd. | 74.23 Billion KRW | -104.666% |
| BNC Korea Co., Ltd. | 14.17 Billion KRW | -972.073% |
| AptaBio Therapeutics Inc. | -13 Billion KRW | 1268.271% |